Payment overview · 2025
General Payments
$121.02
6 reported records · 6 companies
Healthcare provider profile · identity verified
David Maynoldi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ORANGE PARK, FL · NPI 1144591249
Verified facts
What the public records show
CMS Open Payments records show David Maynoldi, M.D. received $121.02 in general payments during 2025 across 6 reported records.
Saluda Medical Americas, Inc. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $27.28 | 22.5% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $23.70 | 19.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.66 | 16.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.85 | 15.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.49 | 13.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.04 | 12.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $121.02 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $27.28 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 240 | 89 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 233 | 47 |
| Dexamethasone | Dexamethasone | 208 | 152 |
| Gabapentin | Gabapentin | 178 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 66 |
| Alprazolam | Alprazolam | 173 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 163 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 57 |
| Azithromycin | Azithromycin | 135 | 112 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 127 | 28 |
| Baclofen | Baclofen | 121 | 69 |
| Meloxicam | Meloxicam | 120 | 48 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 118 | 45 |
| Methocarbamol | Methocarbamol | 111 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 27 |
| Sulindac | Sulindac | 109 | 43 |
| Doxepin Hcl | Doxepin Hcl | 105 | 33 |
| Lisinopril | Lisinopril | 103 | 38 |
| Metformin Hcl Er | Metformin Hcl | 103 | 40 |
| Lansoprazole | Lansoprazole | 98 | 51 |
| Minocycline Hcl | Minocycline Hcl | 91 | 47 |
| Tramadol Hcl | Tramadol Hcl | 90 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 28 |
| Finasteride | Finasteride | 79 | 31 |
| Cefdinir | Cefdinir | 73 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 72 | 31 |
| Pregabalin | Pregabalin | 72 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 24 |
| Metformin Hcl | Metformin Hcl | 70 | 22 |
| Omeprazole | Omeprazole | 69 | 28 |
| Azelastine Hcl | Azelastine Hcl | 67 | 36 |
| Celecoxib | Celecoxib | 66 | 26 |
| Montelukast Sodium | Montelukast Sodium | 66 | 32 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 65 | 53 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 64 | 18 |
| Ozempic | Semaglutide | 64 | 13 |
| Glimepiride | Glimepiride | 63 | 18 |
| Clonazepam | Clonazepam | 60 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | 20 |
| Carvedilol | Carvedilol | 54 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 28 |
| Simvastatin | Simvastatin | 53 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 21 |
| Potassium Chloride | Potassium Chloride | 51 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 25 |
| Eliquis | Apixaban | 48 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 48 | 17 |
| Losartan Potassium | Losartan Potassium | 48 | 23 |
| Propranolol Hcl | Propranolol Hcl | 48 | 16 |
| Nifedipine Er | Nifedipine | 47 | 22 |
| Temazepam | Temazepam | 47 | 11 |
| Furosemide | Furosemide | 44 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 26 |
| Meclizine Hcl | Meclizine Hcl | 42 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 40 | 22 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Valsartan | Valsartan | 39 | 14 |
| Ezetimibe | Ezetimibe | 38 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 26 |
| Prednisone | Prednisone | 36 | 14 |
| Allopurinol | Allopurinol | 35 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 35 | 25 |
| Candesartan Cilexetil | Candesartan Cilexetil | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Torsemide | Torsemide | 34 | 12 |
| Bumetanide | Bumetanide | 33 | 13 |
| Buspirone Hcl | Buspirone Hcl | 33 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 15 |
| Leflunomide | Leflunomide | 31 | 12 |
| Ciclopirox | Ciclopirox | 30 | 17 |
| Colchicine | Colchicine | 30 | 21 |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Tadalafil | Tadalafil | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | 11 |
| Famotidine | Famotidine | 28 | 15 |
| Galantamine Er | Galantamine Hbr | 28 | suppressed |
| Metronidazole | Metronidazole | 27 | 22 |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 19 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | 13 |
| Ssd | Silver Sulfadiazine | 26 | 12 |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Topiramate | Topiramate | 25 | 13 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 23 | 16 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 23 | 18 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | 15 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Terconazole | Terconazole | 18 | 12 |
| Acetic Acid | Acetic Acid | 17 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Imiquimod | Imiquimod | 17 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | 15 |
| Prasugrel Hcl | Prasugrel Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lactulose | Lactulose | 16 | 13 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Armodafinil | Armodafinil | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $121.02 · 6 records | Saluda Medical Americas, Inc. | Cologuard Collection Kit, Evoke, JARDIANCE, REXULTI, Senza, XYOSTED | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error